Eating Disorders and GLP-1 RAs

About this resource

Glucagon-like peptide-1receptor agonists (GLP-1 RAs), such as semaglutide (Ozempic), are medications
originally developed to treat type 2 diabetes. GLP-1 RAs are now being used as an approved or off-label treatment for weight loss and have been trialled as a treatment for some eating disorders such as binge eating disorder (BED).

There is limited research available to help researchers, clinicians and patients/consumers to understand 
the relationships between GLP-1 RAs and eating disorders. However, it is thought that GLP-1 RAs may 
negatively impact eating disorder symptomology and treatment in a number of ways.

This factsheet provides information about GLP-1 RAs as well as their possible interaction with eating disorders including physical and psychological impacts. Practice points are provided for clinicians.

PDF Available ?Yes
Year2025

See also

Eating Disorder Safe principles

Read more

Mind, Body & Fertility: The Connection Between Fertility Care, Disordered Eating and Eating Disorders

People seeking fertility care are significantly more likely than the general population to have an experience of body image issues, disordered eating or an eating disorder.

Read more

Issue 64 | Members' Meeting and Peer Work Guide

NEDC e-Bulletin Editor's Note: It is strange to reflect on the 10th anniversary NEDC Members’ Meeting 2020, held only a month ago on February 27-28 in Melbourne, with the knowledge of the drastic changes made to society due to the COVID-19 pandemic.

Read more

Eating Disorders & GLP-1 RAs

Glucagon-like peptide-1receptor agonists (GLP-1 RAs), such as semaglutide (Ozempic), are medications originally developed to treat type 2 diabetes.

Read more